BELD                                                melanoma(101)
 _________________________________________________________________
  bleomycin....... 15 U SC on days 1 and 4.
  vindesine....... 3 mg/sqm IV on days 1 and 5.
  lomustine....... 80 mg/sqm (maximum single dose 150 mg) orally 
                   day 1.
  dacarbazine..... 200 mg/sqm/day (maximum single dose 400 mg) IV 
                   from day 1 to day 5.
  FREQUENCY....... Repeat cycle every 4 to 6 weeks.

  reference...
    Young DW.  Lever RS.  English JS.  MacKie RM. The use of BELD 
    combination chemotherapy (bleomycin, vindesine, CCNU, and 
    DTIC) in advanced malignant melanoma. Cancer.  55(9):1879-81, 
    1985 May 1. 
  abstract...
    Twenty-one patients with Stage III malignant melanoma have 
    been treated with a 5-day quadruple chemotherapy regime (BELD) 
    comprising bleomycin 15 mg subcutaneously on days 1 and 4, 
    vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, 
    CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 
    intravenously on days 1 through 5. Twenty patients were 
    evaluated after two cycles. Three (15%) are in complete 
    remission 12, 16, and 53 weeks after therapy, respectively, 
    and six (30%) experienced worthwhile partial remissions. This 
    combined response rate of 45% is considerably better than that 
    seen in single- or dual-agent chemotherapy. Toxicity was 
    acceptable, and several patients received their therapy on an 
    outpatient (ambulatory) basis. The one nonevaluable patient 
    had radiotherapy for an isolated spinal metastasis and two 
    courses of BELD. She is well and pain- and disease-free 56 
    weeks later. The median survival for all treated patients is 
    43 weeks, and the median follow-up time is now 63 weeks.